Websites (accreditated)
AA Info

Author: Gianpiero Pescarmona
Date: 14/03/2008

Description

Figure Varie interessanti

Faculty of 1000

We are writing to inform you of an open access repository from Faculty of 1000 (http://f1000.com) (developed by the founders of open access), called F1000 Posters), which covers posters from the leading biology and medicine conferences. Since its launch in June 2010, it has grown quite considerably, and now includes posters from over 180 international meetings, with some of our top-performing posters receiving 400-850 views in a month. We thought you may be interested to inform your researchers about this free new tool which aims to provide indefinite access to the latest developments presented at conferences, but often several months or even years before they are published. We have created a series of 3 posters and wondered whether you might be willing to help us by putting these up around the relevant areas in your institution.

There are a few options:
* You (or a colleague) could download the posters (A4 size - http://f1000posters.com/doc/F1000_Posters_A4.pdf; A3 size - http://f1000posters.com/doc/F1000_Posters_A3.pdf, US letter size - http://f1000posters.com/doc/F1000_Posters_USLetter.pdf) and then just print them yourself and place them in the appropriate places

  • We would be happy to send you professionally printed copies of the posters - just tell us which size you prefer - small (A4) or large (A3) - and the best mailing address to use
  • We could send you banner-type versions of these posters to put on your institutional pages as appropriate (or simply some text and a logo) - just tell us what you require
  • Additionally, do you know of any students who might be keen to earn a little extra money by putting up a whole series of posters around all the relevant departments on your campus? We would then mail them a whole batch of printed posters.

Many thanks for any help with this and do let us know if you have any questions.

Best wishes
Rebecca

Rebecca Lawrence, PhD
Director, New Product Development

FACULTY of 1000
http://F1000.com

World bank open access

Come parte dell'iniziativa “Open Access Policy”, la Banca Mondiale ha
lanciato data.worldbank.org, un sito Web che fornisce un accesso libero e
semplice alle statistiche e agli indicatori sullo sviluppo. Il Catalogo
dei dati a disposizione fornirà l'accesso a oltre 2.000 indicatori da
fonti di dati World Bank. Gli utenti dovranno includere l'attribuzione,
specificando la fonte dei dati, ma saranno liberi di riprodurre,
distribuire, adattare, visualizzare o inserire i dati in altri prodotti
per fini commerciali e non.

L'iniziativa è parte della decisione della Banca mondiale di rendere i
propri dati più accessibili, e il sito fornisce un accesso user-friendly
alle informazioni disponibile in quattro lingue: inglese, spagnolo,
francese e arabo.

Questa nuova iniziativa coincide con la pubblicazione dell’edizione 2010
del World Development Indicators (WDI), una delle risorse più importanti
della Banca mondiale legate alla ricerca statistica. Oltre a fornire
accesso aperto alla WDI, verrà offerto l'accesso aperto anche alle
seguenti risorse: Global Development Finance (GDF), Africa Development
Indicators, Global Economic Monitor, e gli indicatori da Doing Business
Report.

Maggiori informazioni su
Per l’accesso alla maschera di ricerca: databank.worldbank.org/ddp/home.do

da valutare

How stuff works

Knol from Google

OpenWetWare

LifeScienceConnect Colin Hopkins

Biomed Experts Network

Medpedia

Spectrum of Diseases by Therapeutic Area FDA

Health on the net

Medicina in Rete 2001

Allergies and infectious diseases, PublicHealthDegree

ScienceRoll Site

Software

Experiment Flowcharts

Proteins

Center on Proteolytic Pathways

Pathogen - Host Interaction

The Pathogen - Host Interaction database contains expertly curated molecular and biological information on genes proven to affect the outcome of pathogen-host interactions. The database was created and is maintained by researchers at Rothamsted Research and external collaborators.

PHI-base

Genetics

Genetics Home Reference at NLM

Drugs Info

official database of the IUPHAR Committee on Receptor Nomenclature and Drug Classification.

A almost complete list of hormones and neurotransmitters receptors and membrane ion channels created by IUPHAR
It Incorporate the IUPHAR Database of G Protein-Coupled Receptors and the IUPHAR Database of Voltage-Gated and Ligand-Gated Ion Channels.

Food and Drugs Administration

Pharmacorama - Drugs knowledge

Search Engines

Masterkey, metamotore che interroga fonti Open Access, compresa wikipedia

ScienceRoll Search Engine

All+

relemed

ReleMed è un motore di ricerca che interroga la base di
dati MEDLINE. Basta inserire una o alcune parole, e
ReleMed ricerca in MEDLINE i risultati migliori per la tua
domanda, mettendo in cima all'elenco i risultati più
rilevanti.
La differenza rispetto a PubMed è che pur trovando quasi
gli stessi articoli, ReleMed li mostra in un ordine
differente, con i più rilevanti in testa.

Nuovo motore di ricerca per mat. biomedico - OREFIL
database proteine
ncibi

Rare Diseases

Orphanet

University Sites

Tulane

Wikinu francese

Papers List

Publicationslist

Epidemiology

Surveillance, Epidemiology and End Results - SEER -

A premier source for cancer statistics in the United States. SEER collects information on incidence, survival, and prevalence from specific geographic areas representing 26 percent of the US population and compiles reports on all of these plus cancer mortality for the entire US. This site is intended for anyone interested in US cancer statistics or cancer surveillance methods.

Scientific Video Collections

NIH video casting

  • NIH video conferences

Journal of Visualized Experiments
ISSN 1940-087X

  • List of experimental protocols
  • un periodico peer-revieved e ad accesso libero che ha l'interessante caratteristica di pubblicare brevi contributi video per facilitare l'apprendimento delle tecniche di laboratorio (ambito biologico) .
  • The time and resource-consuming process of learning and staying current with techniques and procedures is a rate-limiting step in the advancement of scientific research and drug discovery*

tariffe annue dal 2009 tra 1000 e 2400 $

New video-articles have been published on JoVE
describing experimental approaches in

Neuroscience
Immunology
Developmental Biology
Medicine
Psychology

Some examples:

Medicine: Human In-Vivo Bioassay for the Tissue-Specific Measurement of Nociceptive and Inflammatory Mediators
Angst et al., Stanford University School of Medicine

Psychology: Functional Imaging with Reinforcement, Eyetracking, and Physiological Monitoring
Ferrera et al., Columbia University

Neuroscience: Preparation and Maintenance of Dorsal Root Ganglia Neurons in Compartmented Cultures
Pazyra-Murphy et al., Harvard Medical School

JoVE (Journal of Visualized Experiments) is a peer reviewed and PubMed-indexed research video journal. Please consider publishing a video article on experimental techniques or clinical
procedures applied in your laboratory. Video production can be conducted by our staff.

Complexity

Unpicking the complexity of human disease 2008

Cardiology

Alternative but reasonable site for Cardiology and more

Strano ma da valutare

Servizi Sanitari Nazionali

NHS UK

Neuroscience

Neuroguide

Open Data

Dear Dr. Pescarmona,

I am writing to invite you to submit a manuscript to the recently launched journal
Dataset Papers in Cell Biology, which is part of a series of journals published by
Datasets International (http://www.datasets.com/). Dataset Papers in Cell Biology is
an open access journal that is focused entirely on the publication of Dataset
Papers, which are relatively short articles that describe a piece of experimental or
observational data that an author has collected. Alongside each Dataset Paper, a
copy of the underlying data that is described in the paper will be made freely
available for readers to download.

Authors are welcome to submit Dataset Papers that describe either a piece of data
that has already been discussed in a traditional research article, or a manuscript
describing a new set of data that has not yet been discussed in a research article.
Manuscripts submitted to Dataset Papers in Cell Biology should contain a detailed
explanation of the methodology and materials used in conducting the experiment, as
well as enough metadata about the accompanying dataset to make this data clear and
useful for other researchers. More detailed information can be found in the
journal's author guidelines, which are located at
http://www.datasets.com/journals/cb/guidelines/.

The journal has a distinguished Editorial Board composed of leading cell biology
researchers from around the world, a list of whom can be found at
http://www.datasets.com/journals/cb/editors/. Dataset Papers in Cell Biology is
published using an open access publication model, meaning that all interested
readers are able to freely access the journal online without the need for a
subscription. The journal does not currently require any page charges, color
charges, or article processing charges, and authors will not be charged any fee for
the hosting of their underlying data.

Manuscripts should be submitted to the journal online at
http://mts.datasets.com/author/submit/cb/. Once a manuscript has been accepted for
publication, it will undergo language copyediting, typesetting, and reference
validation in order to provide the highest publication quality possible.

Please do not hesitate to contact me if you have any questions about the journal.

Best regards,

Soha Labib

Tools
Comments
2009-05-12T08:28:09 - Elena Giglia

http://nihlibrary.nih.gov/LibraryServices/path_res.htm
immagini di vie metaboliche

2009-03-17T22:17:26 - Gianpiero Pescarmona

New OA search tool for PubMed
Kevin Davies, Bioalma Launches Novoseek PubMed Search
Tool, Bio-IT World, February 3, 2009. (Thanks to
ResourceShelf.)

Bioalma, the Spanish biomedical IT/text-mining
company, has launched a free search tool for the
PubMed literature database called novo|seek, which the
company claims provides intelligent search
functionality to help life scientists guide and refine
their searches of the biomedical literature.

The company calls novo|seek “a dynamic information
extraction system” for searching biomedical records in
repositories, particularly PubMed. Novo|seek indexes
the biomedical literature in PubMed and enables
researchers to find relevant results efficiently by
using external sources of data and contextual term
information. The tool provides familiar chronological
listings of search results, but a sidebar presents a
series of additional related terms based on relevancy,
allowing researchers to drill down and refine
additional queries. ...

Bioalma downloads and indexes 18 million documents in
Medline each day. That information is then put into
the company’s own database using the open-source
Lucene search engine library. ...

While Bioalma believes that novo|seek will help
introduce its other products to a broader audience, it
also hopes to generate revenue by selling online
advertizing through Google ads, targeting companies
selling reagents or equipment. Bioalma has not held
discussions with NCBI about the tool. ...

The first release of novo|seek focuses on PubMed, but
in time Bioalma plans to integrate additional
resources, such as grant information and full-text
search.
--

http://www.earlham.edu/~peters/fos/2009/02/open-data-from-merck.html
Friday, February 27, 2009

Open data from Merck

John Wilbanks, Sage - Open Access Data from Merck, Common
Knowledge, February 27, 2009. Excerpt:

Big news today at the CHI Medicine Tri-Conference.
Merck has pledged to donate a remarkable resource to
the commons - a vast database of highly consistent
data about the biology of disease, as well as software
tools and other resources to use it. The resources
come out of work done at the Rosetta branch of
Merck....In use inside Rosetta/Merck last year alone
it led directly to a ton of publications.

This is all going to happen through the establishment
of a non-profit organization called Sage to serve as
the guardian of the resources. It's not about making a
quick data dump onto the web, however. Sage is going
to take a while during an "incubation period of three
to five years...in which new project data are
generated, critical tools for building and mining
disease models are developed and governing rules for
sharing, accessing, and contributing to the platform
are established."

This is complex content and it's going to take some
ongoing work to expose everything in a usable way. But
the resources are headed for the public domain, and
will be a remarkable capacity builder for those who
currently work without the best tools and data as a
base for their science. Sage means that we are now on
the path to a world in which scientists working on HIV
in Brazilian non-profit research institutes (like my
mother-in-law) will be able to use the same powerful
computational disease biology tools as those inside
Merck. I'm very much looking forward to living in that
world.

I am proud to serve on the founding Board of Directors
for Sage. I hope to play a role in making sure that
the Open Access part of Sage's mission comes to life
in a way that not only keeps the content and resources
available to all, but serves as a key for future
growth and applications. The law isn't the big story
here - the science is - but if we can get the law
right, it can catalyze the emergence of a robust
public domain in disease biology for us all to benefit
from.

This is an incredibly significant step on the road to
open biology - time will tell if it's as earthshaking
as IBM's embrace of GNU/Linux - and I can't wait to
see where it all goes. Congratulations to the team
that built this platform and then had the vision to
take it into the commons.

Comments

* Kudos to Merck for this unusually beneficial change
of policy. Kudos too for the good judgment to put
Wilbanks on the Board.
* Less than two weeks ago, GlaxoSmithKline (GSK) also
took a large step toward sharing its knowledge and
intellectual property. We can't say that the pharma
industry is collectively moving toward OA. But it's
showing a pattern of large and small steps toward what
some call pre-competitive sharing. See our past posts
on OA-related activity at BIOS and Cambia, Celera,
Collaborative Drug Discovery, Galapagos, GSK, Lilly,
Merck, Novartis, Pfizer, and Synaptic Leap. The best
analysis of this trend I've read is still Tapscott and
Williams from March 2007.

Attachments
fileuserdate
Medicina_in_Rete.htmgp18/03/2008
AddThis Social Bookmark Button